Jul 15, 2021 / 01:00PM GMT
Operator
Hello, and welcome to the Orexo AB Q2 report of 2021. (Operator Instructions)
Today, I'm pleased to present Nikolaj Sørensen, Chief Executive Officer. Please begin your meeting.
Nikolaj Sørensen - Orexo AB(publ)-President&CEO
Thank you very much, and again, welcome to the first half results for Orexo. It's no doubt today has been a sweaty day not only due to the heat wave in Sweden, but also with looking at our share price. However, when I'm looking into our [Q] report and looking at the progress we have made on both ZUBSOLV and also on our digital therapies, I think there are some quite strong reasons to be optimistic about the development moving forward.
And with that, I will start the presentation, and I will go into Page #4. So Page 4. A short summary of the quarter here. So if we look at the U.S. Pharma business, we have seen a stable sales comparing to the last quarter. The positive part is that our core segment, the open market, in particular, the open commercial
Q2 2021 Orexo AB Earnings Call Transcript
Jul 15, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers